前列腺特异性膜抗原作为实体瘤血管导向治疗策略的靶点。

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-11-17 DOI:10.1016/j.critrevonc.2024.104556

Jisce R. Puik , Chung Le , Geert Kazemier , Daniela E. Oprea-Lager , Rutger-Jan Swijnenburg , Elisa Giovannetti , Arjan W. Griffioen , Elisabeth JM Huijbers

{"title":"前列腺特异性膜抗原作为实体瘤血管导向治疗策略的靶点。","authors":"Jisce R. Puik , Chung Le , Geert Kazemier , Daniela E. Oprea-Lager , Rutger-Jan Swijnenburg , Elisa Giovannetti , Arjan W. Griffioen , Elisabeth JM Huijbers","doi":"10.1016/j.critrevonc.2024.104556","DOIUrl":null,"url":null,"abstract":"<div><div>Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104556"},"PeriodicalIF":5.5000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors\",\"authors\":\"Jisce R. Puik , Chung Le , Geert Kazemier , Daniela E. Oprea-Lager , Rutger-Jan Swijnenburg , Elisa Giovannetti , Arjan W. Griffioen , Elisabeth JM Huijbers\",\"doi\":\"10.1016/j.critrevonc.2024.104556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"205 \",\"pages\":\"Article 104556\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-11-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1040842824002993\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002993","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

前列腺特异性膜抗原（PSMA）是少数几种已成功应用于临床的前列腺癌治疗生物标记物之一。在前列腺癌中，PSMA 在肿瘤细胞的细胞膜上过度表达，使其成为使用基于尿素的小分子抑制剂或与放射性同位素结合的抗体进行干预的可行靶点。有趣的是，在几种非前列腺癌中，PSMA 的表达似乎与肿瘤新生血管有关。这为针对非前列腺癌血管的治疗提供了新的治疗机会。在这篇综述中，我们将讨论 PSMA 及其作为血管定向治疗方法靶点的潜力，包括放射性配体疗法、融合蛋白疫苗接种和 CAR T 细胞疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors

Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.